Free tool
FAERS Monitor: Exxua
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021164 or its brand name (Exxua, Gepirone Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
4
Serious
1
25% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- panic attack2
- anger1
- anxiety1
- blood pressure increased1
- drug ineffective1
- headache1
- illness1
- insomnia1
- migraine1
- muscle twitching1
- nervousness1
- overdose1
- product communication issue1
- rash papular1
- suicidal ideation1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2026 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,155 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product communication issue | 1 | 596.1 | 109.2 | 148 |
| panic attack | 2 | 288.6 | 108.3 | 322 |
| rash papular | 1 | 234.6 | 43.0 | 58 |
| muscle twitching | 1 | 228.1 | 41.8 | 56 |
| anger | 1 | 155.5 | 28.5 | 38 |
| nervousness | 1 | 100.7 | 18.4 | 24 |
| suicidal ideation | 1 | 57.4 | 10.5 | 13 |
| migraine | 1 | 55.1 | 10.1 | 13 |
| illness | 1 | 51.0 | 9.3 | 12 |
| blood pressure increased | 1 | 34.4 | 6.3 | 8 |
| overdose | 1 | 24.4 | 4.5 | 5 |
| insomnia | 1 | 19.7 | 3.6 | 4 |
| anxiety | 1 | 18.5 | 3.4 | 4 |
| headache | 1 | 8.4 | 1.5 | 1 |
| drug ineffective | 1 | 4.0 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.